Cargando…

Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT)

Carboxypeptidase G2 (CP) is a bacterial enzyme, which is targeted to tumours by an antitumour antibody for local prodrug activation in antibody-directed enzyme prodrug therapy (ADEPT). Repeated cycles of ADEPT are desirable but are hampered by human antibody response to CP (HACA). To address this, w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mayer, A, Sharma, S K, Tolner, B, Minton, N P, Purdy, D, Amlot, P, Tharakan, G, Begent, R H J, Chester, K A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2004
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409521/ https://www.ncbi.nlm.nih.gov/pubmed/15162148 http://dx.doi.org/10.1038/sj.bjc.6601888

Ejemplares similares

Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material
por: Webley, S D, et al.
Publicado: (2001)

Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
por: Rogers, G. T., et al.
Publicado: (1995)

Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo
por: Theys, J, et al.
Publicado: (2006)

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours
por: Francis, R J, et al.
Publicado: (2002)

Use of horseradish peroxidase for gene-directed enzyme prodrug therapy with paracetamol
por: Tupper, J, et al.
Publicado: (2004)

Encapsulation into sterically stabilised liposomes enhances the immunogenicity of melanoma-associated Melan-A/MART-1 epitopes
por: Adamina, M, et al.
Publicado: (2004)

Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)
por: Monks, N R, et al.
Publicado: (2000)

ADEPT IN THE SCIENCES
Publicado: (1963)

Short communication: A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy
por: Deckert, P M, et al.
Publicado: (2003)

Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil
por: Palmer, D H, et al.
Publicado: (2003)

A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs
por: Spooner, R A, et al.
Publicado: (2003)

E. coli NfsA: an alternative nitroreductase for prodrug activation gene therapy in combination with CB1954
por: Vass, S O, et al.
Publicado: (2009)

Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity
por: Rephaeli, A, et al.
Publicado: (2007)

New guidelines for research in airway device evaluation: time for an updated approach (ADEPT-2) to the Difficult Airway Society’s ‘ADEPT’ strategy?
por: Athanassoglou, V., et al.
Publicado: (2022)

Peripheral macrophages not ADept at amyloid clearance
por: Jay, Taylor, et al.
Publicado: (2015)

So you want to be an ADEPT Fellow?
por: Donaghy, Grainne, et al.
Publicado: (2016)

Anti-tumour activity and toxicity of the new prodrug9-aminocamptothecin glucuronide (9ACG) in mice
por: Prijovich, Z M, et al.
Publicado: (2002)

APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia
por: Viriyakosol, Suganya, et al.
Publicado: (2019)

In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles
por: Bradshaw, T D, et al.
Publicado: (2002)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Challenges and opportunities integrating LLAMA into AdePT
por: Gruber, Bernhard Manfred, et al.
Publicado: (2023)

ADEPT - Abnormal Doppler Enteral Prescription Trial
por: Leaf, Alison, et al.
Publicado: (2009)

OneAPI for simulation: the AdePT project
por: Dosaru, Daniel-Florin
Publicado: (2021)

Alanine Scanning Mutagenesis of the MEDI4893 (Suvratoxumab) Epitope Reduces Alpha Toxin Lytic Activity In Vitro and Staphylococcus aureus Fitness in Infection Models
por: Tkaczyk, C., et al.
Publicado: (2018)

Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
por: Hughes, Derralynn A, et al.
Publicado: (2017)

A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug
por: de Graaf, M, et al.
Publicado: (2002)

Enhanced immunogenicity of a functional enzyme by T cell epitope modification
por: Mucha, Jeanette M, et al.
Publicado: (2002)

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
por: Liu, W M, et al.
Publicado: (2010)

Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles
por: Win, S J, et al.
Publicado: (2012)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes
por: Calcagno, A M, et al.
Publicado: (2008)

In vitro evaluation of cancer-specific NF-κB-CEA enhancer–promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines
por: Guo, X, et al.
Publicado: (2007)

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer
por: Imai, K, et al.
Publicado: (2011)

Pseudomonas aeruginosa NfsB and nitro-CBI-DEI – a promising enzyme/prodrug combination for gene directed enzyme prodrug therapy
por: Green, Laura K, et al.
Publicado: (2013)

PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index
por: Casazza, Andrea, et al.
Publicado: (2022)

Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models
por: El-Emir, E, et al.
Publicado: (2007)

The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1
por: Potter, G A, et al.
Publicado: (2002)

Bacterial amidohydrolases and modified 5-fluorocytidine compounds: Novel enzyme-prodrug pairs
por: Preitakaitė, Viktorija, et al.
Publicado: (2023)

Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)
por: Denny, William A
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_l8kjonip3gmtg82h5odv1tsjqe